# Clinical Research on Endocannabinoid System in Mental Health RCTs > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-clinical-research-mental-health-rcts/ > **Published:** 2026-03-11T17:51:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:09:02-04:00 > **Clinical Summary:** Explore endocannabinoid system clinical research mental health RCTs focusing on digital interventions for university students' mental health and substance use. --- #### Clinical Takeaway A randomized controlled trial tested the Minder mobile app, co-developed with university students, to address mental health and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) challenges during the college transition period. Digital tools like Minder are being studied because they can reach large student populations in a scalable and accessible way. Results from this trial provide clinical evidence on whether app-based interventions can meaningfully improve mental health and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) outcomes in this high-risk demographic. ### #4 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial. **Citation:** Vereschagin Melissa et al. *Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.* Journal of medical Internet research. 2024. PMID: 38536225. **Study type:** Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov’t  |  **Topic area:** Anxiety & PTSD  |  **CED Score:** 12 Design: 5 Journal: 0 N: 3 Recency: 1 Pop: 2 Human: 1 Risk: 0 Why This Matters This randomized controlled trial evaluates a scalable digital intervention that addresses the critical clinical gap in mental health and substance use support during the high-risk transition period of university attendance, when both conditions typically emerge. The study’s findings on the Minder app’s effectiveness provide evidence for whether mobile health interventions can meaningfully improve clinical outcomes in this vulnerable population, potentially informing [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) guidelines and resource allocation for university mental health services. By testing a student-codeveloped intervention, the research determines whether participatory design approaches produce clinically meaningful improvements compared to standard care or control conditions. **Abstract:** BACKGROUND: University attendance represents a transition period for students that often coincides with the emergence of mental health and substance use challenges. Digital interventions have been identified as a promising means of supporting students due to their scalability, adaptability, and acceptability. Minder is a mental health and substance use mobile app that was codeveloped with university students. OBJECTIVE: This study aims to examine the effectiveness of the Minder mobile app in improving mental health and substance use outcomes in a general population of university students. METHODS: A 2-arm, parallel-assignment, single-blinded, 30-day randomized controlled trial was used to evaluate Minder using intention-to-treat analysis. In total, 1489 participants were recruited and randomly assigned to the intervention (n=743, 49.9%) or waitlist control (n=746, 50.1%) condition. The Minder app delivers evidence-based content through an automated chatbot and connects participants with services and university social groups. Participants are also assigned a trained peer coach to support them. The primary outcomes were measured through in-app self-assessments and included changes in general anxiety symptomology, depressive symptomology, and alcohol consumption risk measured using the 7-item General [Anxiety Disorder](https://cedclinic.com/cannabis-adolescent-psychiatric-risk-data-study/) scale, 9-item Patient Health Questionnaire, and US Alcohol Use Disorders Identification Test-Consumption Scale, respectively, from baseline to 30-day follow-up. Secondary outcomes included measures related to changes in the frequency of substance use (cannabis, alcohol, opioids, and nonmedical stimulants) and mental well-being. Generalized linear mixed-effects models were used to examine each outcome. RESULTS: In total, 79.3% (589/743) of participants in the intervention group and 83% (619/746) of participants in the control group completed the follow-up survey. The intervention group had significantly greater average reductions in anxiety symptoms measure Clinical Perspective This randomized controlled trial examining a student-codeveloped mental health and substance use app addresses a genuine clinical need, as university years often mark critical windows for intervention in emerging psychiatric and addiction disorders. The study’s strength lies in its pragmatic design and focus on digital accessibility for a population that may underutilize traditional care, yet we should note that app-based interventions typically show larger effects in controlled research settings than in real-world deployment, and outcomes likely depend heavily on user engagement rates, which remain a significant limitation in digital mental health. Additionally, the abstract does not specify whether substance use outcomes were measured objectively or by self-report, which matters considerably when assessing intervention efficacy in this domain. For clinicians, the key takeaway is that while such tools may serve as useful adjuncts to standard care or as low-barrier entry points for students reluctant to seek in-person evaluation, they should not be positioned as replacements for comprehensive assessment and direct clinical contact when substance use or moderate to severe mental health conditions are present.  |   |  Further Reading Cannabis Policy Wire[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[AM Study Update: March 11, 2026](https://cedclinic.com/cannabis-clinical-research-2026-march-11-update/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/38536225/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007604/)[DOI ↗](https://doi.org/10.2196/54287) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Research: Cannabis in Mental Health RCTs](https://cedclinic.com/digital-mental-health-intervention-cannabis-rcts/) Explore comprehensive research on cannabis and the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in mental health randomized controlled trials. [Read More](https://cedclinic.com/digital-mental-health-intervention-cannabis-rcts/) [endocannabinoid system clinical research: Cannabis RCT Evidence](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-insights/) Review clinical evidence from randomized controlled trials on cannabis and the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). [Explore Evidence](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-insights/) [endocannabinoid system clinical research: RCT findings](https://cedclinic.com/effectiveness-minder-mobile-mental-health-rct-findings/) Detailed findings from randomized controlled trials investigating the endocannabinoid system in clinical settings. [View Findings](https://cedclinic.com/effectiveness-minder-mobile-mental-health-rct-findings/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Clinical%20Research%20on%20Endocannabinoid%20System%20in%20Mental%20Health%20RCTs&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-clinical-research-mental-health-rcts%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-clinical-research-mental-health-rcts%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Clinical%20Research%20on%20Endocannabinoid%20System%20in%20Mental%20Health%20RCTs%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-clinical-research-mental-health-rcts%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).